Let’s reconsider modern progestin-only pills during isotretinoin and retinoid therapy

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors would like to thank Johanna Chester for language editing and editorial assistance.

Disclosure statement

G. Grandi received honoraria for sponsored lectures and participation in advisory boards from Bayer AG, Theramex, Exeltis, Organon, Italfarmaco, Opocrin and Gedeon Richter. The authors have no other relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.